Washington State University, PO Box 1495, Spokane, WA 99210-1495, USA.
Diagn Microbiol Infect Dis. 2009 Nov;65(3):288-99. doi: 10.1016/j.diagmicrobio.2009.07.010. Epub 2009 Sep 4.
The Tigecycline Evaluation and Surveillance Trial began in 2004 to monitor the in vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive pathogens. Against Gram negatives (n = 63 699), tigecycline MIC(90)'s ranged from 0.25 to 2 mg/L for Escherichia coli, Haemophilus influenzae, Acinetobacter baumannii, Klebsiella oxytoca, Enterobacter cloacae, Klebsiella pneumoniae, and Serratia marcescens (but was > or =32 for Pseudomonas aeruginosa). Against Gram-positive organisms (n = 32 218), tigecycline MIC(90)'s were between 0.06 and 0.25 mg/L for Streptococcus pneumoniae, Enterococcus faecium, Streptococcus agalactiae, Staphylococcus aureus, and Enterococcus faecalis. The in vitro activity of tigecycline was maintained against resistant phenotypes, including multidrug-resistant A. baumannii (9.2% of isolates), extended-spectrum beta-lactamase-producing E. coli (7.0%) and K. pneumoniae (14.0%), beta-lactamase-producing H. influenzae (22.2%), methicillin-resistant S. aureus (44.5%), vancomycin-resistant E. faecium (45.9%) and E. faecalis (2.8%), and penicillin-resistant S. pneumoniae (13.8%). Tigecycline represents a welcome addition to the armamentarium against difficult to treat organisms.
替加环素评估和监测试验始于 2004 年，旨在监测替加环素和对照药物对全球革兰氏阴性和革兰氏阳性病原体的体外活性。针对革兰氏阴性菌（n = 63699），替加环素 MIC（90）范围为 0.25 至 2mg/L，适用于大肠杆菌、流感嗜血杆菌、鲍曼不动杆菌、催产克雷伯菌、阴沟肠杆菌、肺炎克雷伯菌和粘质沙雷氏菌（但对铜绿假单胞菌的 MIC（90）大于等于 32mg/L）。针对革兰氏阳性菌（n = 32218），替加环素 MIC（90）范围为 0.06 至 0.25mg/L，适用于肺炎链球菌、屎肠球菌、无乳链球菌、金黄色葡萄球菌和粪肠球菌。替加环素对耐药表型仍具有体外活性，包括耐多药鲍曼不动杆菌（9.2%的分离株）、产超广谱β-内酰胺酶的大肠埃希菌（7.0%）和肺炎克雷伯菌（14.0%）、产β-内酰胺酶的流感嗜血杆菌（22.2%）、耐甲氧西林的金黄色葡萄球菌（44.5%）、万古霉素耐药屎肠球菌（45.9%）和粪肠球菌（2.8%）以及青霉素耐药肺炎链球菌（13.8%）。替加环素是治疗难处理病原体的有效武器。
